Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor.

The receptors for insulin and insulin-like growth factor (IGF)-I carry intrinsic tyrosine-specific protein kinases (TPK) in their cytoplasmic domains that show 84% homology. Our previous studies using tyrosine-containing synthetic polymers (Arch. Biochem. Biophys. 260, 416, 1988) revealed subtle differences between the two receptor TPKs. In the present study, low molecular weight kinase inhibitors were used to compare the two receptor TPKs purified from human placenta. Staurosporine was the most potent inhibitor of both receptor TPKs among the three inhibitors tested. It was 100 times more inhibitory to insulin receptor TPK (ED50 = 61nM) than IGF-I receptor TPK (ED50 = 6.2 microM). Apigenin and kaempferol showed approximately the same inhibitory potency toward both TPKs with a range of 10 approximately 1000 microM. Staurosporine is thus an excellent tool to biochemically characterize the two receptor TPKs as well as to selectively inhibit insulin-activated TPK in intact cells.

[1]  D. Lebwohl,et al.  Synthesis, purification, and characterization of the cytoplasmic domain of the human insulin receptor using a baculovirus expression system. , 1988, The Journal of biological chemistry.

[2]  R. Erikson,et al.  The effect of quercetin on the phosphorylatio activity of the Rous sarcoma virus transforming gene product in vitro and in vivo , 1983 .

[3]  M. T. Lipari,et al.  Epidermal growth factor receptor tyrosine kinase phosphorylation of glucose-6-phosphate dehydrogenase in vitro. , 1987, Archives of biochemistry and biophysics.

[4]  J. Ramachandran,et al.  Specificity of tyrosine protein kinases of the structurally related receptors for insulin and insulin-like growth factor I: Tyr-containing synthetic polymers as specific inhibitors or substrates. , 1988, Archives of biochemistry and biophysics.

[5]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[6]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[7]  P. Cuatrecasas,et al.  Purification of insulin-like growth factor I receptor from human placental membranes. , 1986, The Journal of biological chemistry.

[8]  S Omura,et al.  A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. , 1977, The Journal of antibiotics.

[9]  Y. Miyata,et al.  Purified protein kinase C phosphorylates microtubule-associated protein 2. , 1986, The Journal of biological chemistry.

[10]  K. Itakura,et al.  Purification of insulin receptor with full binding activity. , 1983, The Journal of biological chemistry.

[11]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[12]  E. Chambaz,et al.  Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. , 1982, Biochemical pharmacology.

[13]  S. Watson,et al.  The action of the protein kinase C inhibitor, staurosporine, on human platelets. Evidence against a regulatory role for protein kinase C in the formation of inositol trisphosphate by thrombin. , 1988, The Biochemical journal.

[14]  H. Iba,et al.  Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. , 1987, The Journal of antibiotics.

[15]  O. Rosen.  After insulin binds. , 1987, Science.

[16]  T. Tamaoki,et al.  Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. , 1986, Biochemical and biophysical research communications.